Journal of Hematology & Oncology

Papers
(The H4-Index of Journal of Hematology & Oncology is 88. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Targeting the Wnt/β-catenin signaling pathway in cancer823
Nanomaterials for cancer therapy: current progress and perspectives671
Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer463
NK cell-based cancer immunotherapy: from basic biology to clinical development397
Regulation of PD-L1 expression in the tumor microenvironment365
Challenges and advances in clinical applications of mesenchymal stromal cells348
Next generation of immune checkpoint inhibitors and beyond347
Cancer vaccines as promising immuno-therapeutics: platforms and current progress336
The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis323
RNA sequencing: new technologies and applications in cancer research316
Liquid biopsy: current technology and clinical applications315
Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research308
Combination strategies to maximize the benefits of cancer immunotherapy307
Recent advances in therapeutic strategies for triple-negative breast cancer283
Emerging role of exosomes in cancer progression and tumor microenvironment remodeling277
Isolation and characterization of exosomes for cancer research274
Applications of single-cell sequencing in cancer research: progress and perspectives274
Neutrophils in cancer carcinogenesis and metastasis268
Targeting mutant p53 for cancer therapy: direct and indirect strategies266
Novel therapies emerging in oncology to target the TGF-β pathway255
Immunosenescence: a key player in cancer development252
Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response250
Targeting hypoxic tumor microenvironment in pancreatic cancer238
Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells235
Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions235
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets219
Burden of anemia and its underlying causes in 204 countries and territories, 1990–2019: results from the Global Burden of Disease Study 2019217
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy215
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation207
Therapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer200
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)198
Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy196
Gastric cancer treatment: recent progress and future perspectives196
Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies195
Targeting CD47 for cancer immunotherapy190
Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape189
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy180
Targeting MCL-1 in cancer: current status and perspectives177
MEK inhibitors for the treatment of non-small cell lung cancer173
HMGB1 released from GSDME-mediated pyroptotic epithelial cells participates in the tumorigenesis of colitis-associated colorectal cancer through the ERK1/2 pathway169
Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990–2019167
Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies167
Role of lysosomes in physiological activities, diseases, and therapy164
The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update159
Mesenchymal stem/stromal cells in cancer therapy158
Targeted therapy in advanced non-small cell lung cancer: current advances and future trends156
IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin154
Exploring immunotherapy in colorectal cancer151
Antibody–drug conjugates in solid tumors: a look into novel targets146
Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single insti144
The management of metastatic GIST: current standard and investigational therapeutics144
N6-methyladenosine methyltransferases: functions, regulation, and clinical potential143
Targeting autophagy to overcome drug resistance: further developments142
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies139
The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1139
Emerging agents and regimens for AML138
Targeting Akt in cancer for precision therapy132
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts129
The potential role of N7-methylguanosine (m7G) in cancer126
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy125
Emerging strategies to target RAS signaling in human cancer therapy121
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma118
HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk116
The long and short non-coding RNAs modulating EZH2 signaling in cancer116
Development of a novel combined nomogram model integrating deep learning-pathomics, radiomics and immunoscore to predict postoperative outcome of colorectal cancer lung metastasis patients112
The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia112
Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma112
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance111
The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands110
Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications109
Contradictory roles of lipid metabolism in immune response within the tumor microenvironment106
MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents103
A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties102
YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-κB and promote the malignant progression of glioma101
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021100
Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer99
Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials98
MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies97
RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential96
New agents and regimens for diffuse large B cell lymphoma95
Advances in the diagnosis and treatment of sickle cell disease93
Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma92
Tumor organoids: applications in cancer modeling and potentials in precision medicine91
LCAT3, a novel m6A-regulated long non-coding RNA, plays an oncogenic role in lung cancer via binding with FUBP1 to activate c-MYC91
Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors89
FGFR-TKI resistance in cancer: current status and perspectives88
HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA88
COVID-19 vaccines for patients with cancer: benefits likely outweigh risks88
0.041463851928711